Pacira BioSciences, Inc. (PCRX)

The company now

Viatris Inc. agreed on 8 October 2026 to acquire Pacira for $36.50 in cash for each share, an aggregate equity value of $1.65 billion, and both boards approved the deal unanimously 2.

Viatris began the tender offer on 30 October 2026, and it is set to expire late on 16 November 2026 unless extended 4.

The antitrust waiting period under the Hart-Scott-Rodino Act ended late on 29 October 2026 4. The offer also needs at least one share more than 50 percent of all shares tendered 1.

Viatris first offered $31.00 a share on 17 July 2026, and the final terms followed Pacira's counteroffer of $36.50 on 5 October 2026, all in cash with no contingent payment 4. Pacira's board listed activist campaigns that cost time and money among the risks of staying independent 4.

The last results on file are for the second quarter of 2026: revenue of $192.4 million, up 6 percent, with EXPAREL, the larger product, at $147.8 million 6. On 31 July 2026 Pacira closed the sale of its iovera device business to Zimmer for $73.6 million in cash 5.

Viatris says it expects the deal to close by the end of 2026, after which Pacira would leave the Nasdaq as a wholly owned subsidiary 2.

As of Nov 4, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.